Monalisa Hard Dermal Filler
$28.90
Monalisa Hard Dermal Filler is a medical-grade hyaluronic acid injectable containing 24mg/ml cross-linked HA with 0.3% lidocaine. Clinically proven to deliver 89% improvement in glabellar lines with 12-18 month longevity. Manufactured to KGMP standards with <2% BDDE residues for safe volumizing and contouring.
| Mix-And-Match Quantity | Get More Discount | Final Price |
|---|---|---|
| 5-15 | 4% | $27.74 |
| 16-30 | 6% | $27.17 |
| 31-Unlimited | 8% | $26.59 |
Monalisa Hard Dermal Filler
Precision Treatment for Medium-Deep Facial Wrinkles & Lip Enhancement
Professional Grade Filler
Medical-grade hyaluronic acid dermal filler containing 24mg/ml cross-linked HA with 0.3% lidocaine. Clinically proven to deliver 89% improvement in glabellar lines (Phase III trials) with longevity of 12-18 months. KGMP-certified formulation exceeds EU Medical Device Directive 93/42/EEC standards with <2% BDDE residues and <0.5 EU/ml endotoxins for enhanced safety profile.
Key Advantages
Optimal HA Density
24mg/ml concentration for superior volume restoration
Integrated Anesthetic
0.3% lidocaine for enhanced patient comfort
Precision Delivery
1.0ml syringe with 25G/27G needles
Extended Stability
24-month shelf life at 2-25°C
Core Technology
HyaluroLock™ Cross-Linking
Patented cross-linking technology achieves optimal G-prime value (450-550Pa) for:
- Volume maintenance lasting 12+ months
- Natural tissue integration
- Minimal swelling propensity
ISO 13485 Certified | <2% BDDE residues | <0.5 EU/ml endotoxins
Medical Packaging
Packaging Details
- Batch-tracked sterile packaging
- Pre-filled 1.0ml precision syringe
Storage Requirements
- 2-25°C temperature stability
- 24-month shelf life
Clinical Protocol
Injection Technique
- Subcutaneous injection method
- 30°-45° needle angle insertion
- Retrograde linear threading technique
Dosage Guidelines
- Maximum 0.2ml per injection pass
- 25G/27G needle selection
- Staged treatment approach recommended
⚠️ Contraindication: Not for use during pregnancy
Medical Practice Notice
For licensed practitioners only. Not FDA-approved. Adverse event rate: 0.37% in clinical trials (temporary erythema/swelling possible). Genoss Co. certifies compliance with ISO 9001:2015 (QMS) and ISO 13485:2016 (Medical Devices). Results vary based on injection technique and patient physiology. Batch-specific data available upon request.

Reviews
There are no reviews yet.